Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
Oliveira, Mafalda, Pominchuk, Denys, Nowecki, Zbigniew, Hamilton, Erika, Kulyaba, Yaroslav, Andabekov, Timur, Hotko, Yevhen, Melkadze, Tamar, Nemsadze, Gia, Neven, Patrick, Vladimirov, Vladimir, Zamagni, Claudio, Denys, Hannelore, Forget, Frédéric, Horvath, Zsolt, Nesterova, Alfiya, Ajimi, Maxine, Kirova, Bistra, Klinowska, Teresa, Lindemann, Justin P O, Lissa, Delphine, Mathewson, Alastair, Morrow, Christopher J, Traugottova, Zuzana, van Zyl, Ruaan, Arkania, Ekaterine
Published in The lancet oncology (01.11.2024)
Published in The lancet oncology (01.11.2024)
Get full text
Journal Article
Abstract GS3-02: GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial
Oliveira, Mafalda, Pominchuck, Denys, Nowecki, Zbigniew, Hamilton, Erika, Kulyaba, Yaroslav, Andabekov, Timur, Hotko, Yevhen, Melkadze, Tamar, Nemsadze, Gia, Neven, Patrick, Semegen, Yuriy, Vladmirov, Vladmir, Zamagni, Claudio, Denys, Hannelore, Forget, Frederic, Horvath, Zsolt, Nesterova, Alfiya, Bennett, Maxine, Kirova, Bistra, Klinowska, Teresa, Lindemann, Justin, Lissa, Delphine, Mathewson, Alastair, Morrow, Christopher, Traugottova, Zuzana, Van Zyl, Ruaan, Arkania, Ekaterine
Published in Cancer research (Chicago, Ill.) (01.03.2023)
Published in Cancer research (Chicago, Ill.) (01.03.2023)
Get full text
Journal Article